NovaBay Pharmaceuticals Launches Avenova Allograft in the U.S.

NovaBay Pharmaceuticals announced the official launch of the Avenova Allograft in the United States via its physician-dispensed distribution channel. This prescription optic allograft, designed for safeguarding ocular surfaces during repair, is produced using BioStem Technologies' advanced manufacturing process.

This product launch follows a previously disclosed agreement, whereby NovaBay acquired the rights to market BioStem Technologies' Amniotic Tissue Allograft under the Avenova brand. The Avenova allograft will be available in the global ophthalmology amniotic membrane market.

According to NovaBay, the Avenova Allograft offers a protective covering for corneal and conjunctival repair, facilitating the restoration of a healthier ocular surface.

BioStem Technologies will be responsible for the entire process, including manufacturing, packaging, shipping, and regulatory compliance, utilizing its meticulous six-step BioRetain process to maintain the placental tissue's natural integrity.

NovaBay emphasized that the product solely comprises the amnion layer of the placental membrane, with a thickness ranging from 20 to 50 µm, making it ideal for delicate ophthalmic applications. The Avenova Allograft is available in diameters of 8, 10, and 12 mm.

NovaBay's commercial launch of the Avenova Allograft will incorporate outreach initiatives geared towards educating eyecare specialists about both the clinical advantages of the product and the Medicare reimbursement process.

Additionally, NovaBay's Avenova product lineup encompasses various offerings, such as the Avenova antimicrobial lid and lash spray, specially designed dry wipes, lubricating eye drops, a warm eye compress, oral supplements, and the i-Chek mirror for monitoring eyelid health.